whoaaa!!
RECCE® 327 Demonstrates Outstanding Efficacy Against
Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria
Highlights
• RECCE® 327 (R327) shown to reduce deadly ‘flesh-eating’ bacterial count Below Limit of
Quantification (BLOQ) within 24 hours, at varying concentrations
• R327 BLOQ efficacy as early as 30 minutes in C. perfringens – a leading bacterial cause
of myonecrosis (gas gangrene)
1
• 99.9% (3-log) bacterial reduction achieved in all bacteria tested, at various concentrations
• Data demonstrates R327’s potential against bacterial infections that thrive in nil/low
oxygen environments i.e. diabetic wounds/ulcers infections
Ann: Outstanding Efficacy Against Flesh-Eating Bacteria, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $106.9M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 37.0¢ | $10.23K | 27.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3019 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 9138 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| RCE (ASX) Chart |